ABIVAX Société Anonyme (NASDAQ:ABVX) Sees Large Volume Increase

ABIVAX Société Anonyme (NASDAQ:ABVX) shares saw unusually-strong trading volume on Tuesday . Approximately 133,388 shares traded hands during mid-day trading, an increase of 61% from the previous session’s volume of 82,933 shares.The stock last traded at $11.23 and had previously closed at $11.52.

Analysts Set New Price Targets

Separately, Laidlaw began coverage on ABIVAX Société Anonyme in a report on Monday, July 29th. They issued a “buy” rating and a $48.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $36.50.

ABIVAX Société Anonyme Price Performance

The company has a debt-to-equity ratio of 0.48, a current ratio of 3.04 and a quick ratio of 4.08. The firm has a 50-day moving average price of $11.64 and a two-hundred day moving average price of $13.24.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ABVX. Ghisallo Capital Management LLC bought a new position in ABIVAX Société Anonyme in the fourth quarter worth $642,000. Commodore Capital LP bought a new position in ABIVAX Société Anonyme in the fourth quarter worth $20,277,000. Blackstone Inc. bought a new position in ABIVAX Société Anonyme in the fourth quarter worth $25,345,000. Great Point Partners LLC bought a new position in ABIVAX Société Anonyme in the fourth quarter worth $16,585,000. Finally, BNP Paribas Financial Markets bought a new position in shares of ABIVAX Société Anonyme during the first quarter valued at $81,000. 47.91% of the stock is owned by institutional investors.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.